203 related articles for article (PubMed ID: 32594283)
21. Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.
Shen X; DiMario S; Philip K
Adv Ther; 2019 Dec; 36(12):3424-3434. PubMed ID: 31625131
[TBL] [Abstract][Full Text] [Related]
22. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
23. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
[TBL] [Abstract][Full Text] [Related]
24. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
Wong ND; Bang M; Block RC; Peterson ALH; Karalis DG
Am J Cardiol; 2021 Aug; 152():57-62. PubMed ID: 34147211
[TBL] [Abstract][Full Text] [Related]
25. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort.
Vicente-Valor J; García-González X; Ibáñez-García S; Durán-García ME; de Lorenzo-Pinto A; Rodríguez-González C; Méndez-Fernández I; Percovich-Hualpa JC; Herranz-Alonso A; Sanjurjo-Sáez M
Biomed Pharmacother; 2022 Feb; 146():112519. PubMed ID: 34968928
[TBL] [Abstract][Full Text] [Related]
26. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
27. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
[TBL] [Abstract][Full Text] [Related]
28. Application of PCSK9 Inhibitors in Practice.
Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
[TBL] [Abstract][Full Text] [Related]
29. [Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies].
Siniawski D; Masson W; Rossi E; Damonte J; Halsband A; Pizarro R
Medicina (B Aires); 2019; 79(2):104-110. PubMed ID: 31048275
[TBL] [Abstract][Full Text] [Related]
30. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
[TBL] [Abstract][Full Text] [Related]
31. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
32. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Yazdi D; Elliott-Davey M; Mues KE; Bhatt DL; Kosiborod MN;
Am Heart J; 2020 Jan; 219():70-77. PubMed ID: 31726422
[TBL] [Abstract][Full Text] [Related]
33. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand.
Kongpakwattana K; Ademi Z; Chaiyasothi T; Nathisuwan S; Zomer E; Liew D; Chaiyakunapruk N
Pharmacoeconomics; 2019 Oct; 37(10):1277-1286. PubMed ID: 31243736
[TBL] [Abstract][Full Text] [Related]
35. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
[TBL] [Abstract][Full Text] [Related]
36. Effect of an intervention to increase statin use in medicare members who qualified for a medication therapy management program.
Stockl KM; Tjioe D; Gong S; Stroup J; Harada AS; Lew HC
J Manag Care Pharm; 2008; 14(6):532-40. PubMed ID: 18693777
[TBL] [Abstract][Full Text] [Related]
37. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
Canonico ME; Hess CN; Cannon CP
Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
[TBL] [Abstract][Full Text] [Related]
38. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
39. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
40. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]